Mood, Anxiety, and Hormonal Shifts: Untangling the Biology

Mood changes during midlife are common, but the experience can be deeply unsettling, particularly when it seems to come out of nowhere. You have no new stressors, nothing in your life has changed, and yet you feel different — more anxious, more irritable, less resilient, or inexplicably low. For many people, the instinct is to attribute these changes to life circumstances, stress, or personality. But there is a biological explanation that deserves equal consideration: hormones directly influence mood regulation, and the hormonal shifts of midlife can produce mood and anxiety symptoms that are physiological in origin.

How Hormones Influence Mood: The Neurobiology

Mood regulation is governed by neurotransmitters — chemical messengers in the brain that include serotonin, norepinephrine, dopamine, and GABA. Reproductive hormones, particularly estrogen, progesterone, and testosterone, interact directly with these neurotransmitter systems.

Estrogen and Serotonin

Estrogen is one of the strongest modulators of the serotonergic system. It increases tryptophan hydroxylase activity (the enzyme that synthesizes serotonin), enhances serotonin receptor sensitivity, and inhibits monoamine oxidase (the enzyme that breaks down serotonin). When estrogen levels are stable and adequate, serotonin function is supported. When estrogen fluctuates or declines, serotonin function can be disrupted, contributing to depressed mood, irritability, and anxiety.

This mechanism helps explain why women are more vulnerable to depression during periods of hormonal flux: puberty, the premenstrual period, postpartum, and perimenopause. The common thread is not the absolute level of estrogen but the instability and rate of change.

Progesterone and GABA

Progesterone is metabolized to allopregnanolone, a neurosteroid that is a potent positive modulator of GABA-A receptors. GABA is the brain's primary inhibitory neurotransmitter — it reduces neuronal excitability, promotes calm, and facilitates sleep. Allopregnanolone's effect on GABA receptors is comparable in mechanism (though not potency) to benzodiazepines and alcohol.

When progesterone levels are adequate (as in the luteal phase or during pregnancy), this GABAergic effect provides a calming influence. When progesterone declines — as in the premenstrual phase or during perimenopause — the withdrawal of this calming effect can manifest as increased anxiety, restlessness, irritability, and insomnia.

Testosterone and Mood in Both Sexes

Testosterone influences mood in both men and women. In men, low testosterone is associated with increased rates of depression and irritability. The relationship is supported by multiple observational studies and by intervention data showing that testosterone replacement in hypogonadal men can improve mood, particularly in those with mild depressive symptoms.

In women, testosterone is produced by the ovaries and adrenal glands in smaller quantities but still plays a role in energy, motivation, and sense of well-being. Testosterone levels in women decline gradually from the late 20s onward. Whether testosterone supplementation improves mood in women is an area of active research with mixed results.

Perimenopause: A Vulnerable Window

Epidemiological data consistently shows that perimenopause is a period of elevated risk for both new-onset depression and recurrence of prior depression. The Penn Ovarian Aging Study and SWAN have both documented this increased risk.

Key findings from these studies include:

• Women in perimenopause are two to four times more likely to experience a major depressive episode compared to premenopausal women of the same age.
• The risk is highest during the late perimenopausal transition, when hormonal fluctuations are most pronounced.
• Women with a prior history of depression are at even higher risk, but a significant proportion of perimenopausal depression occurs in women with no prior history.
• Vasomotor symptoms (hot flashes) and sleep disruption are independently associated with depressive symptoms but do not fully account for the increased risk. There appears to be a direct hormonal contribution to mood vulnerability beyond the effects mediated by sleep and vasomotor disturbance.

Anxiety: The Underrecognized Symptom

While depression during perimenopause has received significant research attention, anxiety has been relatively underrecognized. Yet many women report that anxiety — not depression — is their primary mood symptom during the menopausal transition. This can manifest as:

• Generalized anxiety or a feeling of constant unease
• Panic attacks, sometimes occurring for the first time
• Heart palpitations (which may overlap with vasomotor symptoms)
• A sense of dread or impending doom without an identifiable cause
• Social anxiety or withdrawal from situations previously handled with ease
• Hypervigilance or exaggerated startle responses

The biological basis likely involves the withdrawal of progesterone's GABAergic calming effect, fluctuations in estrogen affecting serotonin and norepinephrine, and the heightened sympathetic nervous system activity that accompanies vasomotor instability. The experience is physiological, not a character flaw or a sign of weakness.

Distinguishing Hormonal Mood Changes from Primary Mood Disorders

One of the clinical challenges is distinguishing between mood changes driven primarily by hormonal shifts and primary mood disorders (major depression, generalized anxiety disorder) that happen to coincide with midlife. The distinction matters because the treatment approach may differ:

• Timing. Hormonal mood changes typically onset during the perimenopausal transition and may correlate with menstrual cycle changes or vasomotor symptoms. Primary mood disorders can onset at any time and are more often associated with life stressors, genetic predisposition, or trauma history.
• Pattern. Hormonally driven mood changes may fluctuate with the menstrual cycle (in early perimenopause) or with vasomotor episodes. Primary mood disorders tend to be more persistent.
• Symptom profile. Hormonally driven depression in perimenopause may present with more irritability, anger, and anxiety than the classic sadness and hopelessness of major depression, though there is significant overlap.
• Response to treatment. Some women with hormonally driven mood changes respond well to hormone therapy (estrogen with or without progesterone), while primary mood disorders are more likely to respond to antidepressant medication and psychotherapy.

In practice, these categories often overlap. A woman may have hormonal mood instability that triggers a full depressive episode. A man with declining testosterone may develop depression that would benefit from both testosterone optimization and antidepressant therapy. The most effective approach often combines attention to hormonal status with standard psychiatric treatment.

What Helps

Comprehensive Evaluation

If you are experiencing mood or anxiety changes in midlife, start with a thorough evaluation that includes hormonal status (estrogen, progesterone, testosterone, thyroid function), mood screening (standardized questionnaires like the PHQ-9 for depression and GAD-7 for anxiety), and assessment of sleep, stress, and vasomotor symptoms. Do not accept a single-axis explanation when multiple systems may be involved.

Hormone Therapy (When Appropriate)

For women with perimenopausal mood changes that are accompanied by vasomotor symptoms and are not severe enough to constitute a major depressive episode, estrogen therapy has shown benefit. A study published in JAMA Psychiatry in 2015 found that transdermal estradiol was effective for preventing depressive episodes in perimenopausal and early postmenopausal women. Progesterone may have additional mood-stabilizing effects for some women, though responses vary.

For men with documented low testosterone and mild depressive symptoms, testosterone replacement may improve mood, as shown in the Testosterone Trials.

Antidepressant and Anxiolytic Medications

SSRIs and SNRIs are effective for both depression and anxiety in midlife, whether the cause is hormonal, psychosocial, or both. Some SSRIs (paroxetine) and SNRIs (venlafaxine) also reduce vasomotor symptoms, providing a dual benefit for perimenopausal women.

Psychotherapy

Cognitive behavioral therapy (CBT) is effective for depression and anxiety regardless of hormonal status. It provides tools for managing the cognitive and behavioral patterns that perpetuate mood problems. For women in perimenopause, CBT adapted for menopausal symptoms has been specifically studied and shown to be beneficial.

Exercise

Physical activity has consistent evidence for improving both depression and anxiety. The effect size is moderate but meaningful, comparable in some studies to the effect of antidepressant medication for mild to moderate depression. Both aerobic exercise and resistance training appear beneficial.

Sleep

Treating sleep disruption — whether through CBT for insomnia, management of vasomotor symptoms, or treatment of sleep apnea — often produces significant improvement in mood and anxiety. Sleep and mood are deeply intertwined, and addressing one often improves the other.

What Not to Do

• Do not dismiss mood changes as "just hormones" and ignore them. Hormonal mood changes are real and treatable. Dismissing them delays care.
• Do not assume all mood changes are hormonal. A comprehensive evaluation is necessary to identify all contributing factors.
• Do not self-medicate with supplements. Most supplements marketed for hormonal mood support lack rigorous evidence. Some can interact with medications or have unintended hormonal effects.
• Do not suffer in silence. The stigma around mood symptoms, particularly in men, delays evaluation and treatment. These are medical symptoms with medical solutions.

The Bottom Line

Mood and anxiety changes during midlife have a clear biological substrate. Estrogen modulates serotonin. Progesterone modulates GABA. Testosterone influences mood regulation in both sexes. When these hormones shift — as they do during perimenopause and andropause — the neurotransmitter systems they support are disrupted, and mood symptoms can follow.

This is not a weakness. It is physiology. And like any physiological disruption, it can be evaluated, understood, and treated. The first step is recognizing that your mood is a dimension of health that deserves the same attention as your blood pressure or cholesterol — especially when your hormonal landscape is changing.